ReviewMolecules and cells2026
Artificial intelligence and multiomics integration for Parkinson's disease drug development.
Review in Molecules and cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances underscore the potential of integrating multiomics, such as genomics, transcriptomics, proteomics, and metabolomics, and artificial intelligence to overcome limitations regarding early diagnosis and treatment of Parkinson's disease. Developing a comprehensive view of the complex molecular landscape of Parkinson's disease through artificial intelligence algorithms would enable the processing of extensive multiomics datasets. Applying these integrative technologies to Parkinson's disease research would improve early diagnosis, support personalized therapeutic strategies, and drug discovery. This review explores the transformative potential of integrating multiomics and artificial intelligence in Parkinson's disease, outlining a framework to advance diagnosis, treatment, and drug development in neurodegenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.